Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Stem Cell Research

  Free Subscription

Articles published in Leuk Res

Retrieve available abstracts of 14 articles:
HTML format

Single Articles

    March 2023
  1. TERAO Y, Nakayama Y, Abo M, Otobe Y, et al
    Impact of the quantity and quality of the skeletal muscle on survival among patients undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2023;128:107057.
    PubMed     Abstract available

    December 2022
  2. LEBON D, Dujardin A, Caulier A, Joris M, et al
    Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
    Leuk Res. 2022;125:107005.
    PubMed     Abstract available

  3. RAMAN HS, Kim SE, DeAngelo DJ, Stevenson KE, et al
    Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2022;125:107004.
    PubMed     Abstract available

  4. ZHANG Y, Liu C, Zhang R, Shi Y, et al
    Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome.
    Leuk Res. 2022;124:106997.
    PubMed     Abstract available

    October 2022
  5. SHAH N, Cioccio J, Rakszawski K, Zheng H, et al
    Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide.
    Leuk Res. 2022;123:106969.

  6. FUJIWARA SI, Murahashi R, Nakashima H, Matsuoka S, et al
    Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation.
    Leuk Res. 2022;121:106951.
    PubMed     Abstract available

    September 2022
  7. QI K, Hu X, Yu X, Cheng H, et al
    Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia.
    Leuk Res. 2022;120:106920.
    PubMed     Abstract available

    July 2022
  8. VIRK H, Rathore S, Anshu A, Jamwal M, et al
    Imatinib responsive erythrocytosis in a patient with FIP1L1::PDGFRA rearranged myeloid neoplasm with hypereosinophilia - Another manifestation of a stem cell neoplasm.
    Leuk Res. 2022;121:106922.

  9. BARKHORDAR M, Kasaeian A, Janbabai G, Mousavi SA, et al
    Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-yea
    Leuk Res. 2022;120:106918.
    PubMed     Abstract available

  10. BOSTANKOLU DEGIRMENCI B, Yegin ZA, Dikyar A, Aydin Kaynar L, et al
    Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia.
    Leuk Res. 2022;118:106870.
    PubMed     Abstract available

    February 2022
  11. KUSNE Y, Xie Z, Patnaik MM
    Clonal hematopoiesis: Molecular and clinical implications.
    Leuk Res. 2022;113:106787.
    PubMed     Abstract available

    November 2021
  12. MINAKATA D, Fujiwara SI, Murahashi R, Nakashima H, et al
    Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis.
    Leuk Res. 2021;112:106750.
    PubMed     Abstract available

    September 2021
  13. TANG S, Lu Y, Zhang P, Chen D, et al
    Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
    Leuk Res. 2021;110:106710.
    PubMed     Abstract available

  14. SAPELLI J, Filho JS, Matias Vieira GM, Moura FL, et al
    BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
    Leuk Res. 2021;110:106689.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.